15 results on '"Lustigman, Sara"'
Search Results
2. Survival of worm masses of Onchocerca ochengi in gerbils and hamsters: implications for the development of an in vivo macrofilaricide screening model
- Author
-
Ayiseh, Rene Bilingwe, Mbah, Glory Enjong, Manfo, Faustin Pascal Tsague, Kulu, Tessy-Koko, Njotu, Fabrice Ngoh, Monya, Elvis, Ndi, Emmanuel Menang, Tumanjong, Irene Memeh, Mainsah, Evans Ngandung, Sakanari, Judy, Lustigman, Sara, and Cho-Ngwa, Fidelis
- Published
- 2023
- Full Text
- View/download PDF
3. Onchocerca volvulus bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice
- Author
-
Ryan, Nathan M., Hess, Jessica A., de Villena, Fernando Pardo-Manuel, Leiby, Benjamin E., Shimada, Ayako, Yu, Lei, Yarmahmoodi, Amir, Petrovsky, Nikolai, Zhan, Bin, Bottazzi, Maria Elena, Makepeace, Benjamin L., Lustigman, Sara, and Abraham, David
- Published
- 2021
- Full Text
- View/download PDF
4. Combinations of the azaquinazoline anti-Wolbachia agent, AWZ1066S, with benzimidazole anthelmintics synergise to mediate sub-seven-day sterilising and curative efficacies in experimental models of filariasis.
- Author
-
Hegde, Shrilakshmi, Marriott, Amy E., Pionnier, Nicolas, Steven, Andrew, Bulman, Christina, Gunderson, Emma, Voge, Ian, Kosche, Marianne, Ehrens, Alexandra, Lustigman, Sara, Voronin, Denis, Tricoche, Nancy, Hoerauf, Achim, Hübner, Marc P., Sankanari, Judy, Aljayyoussi, Ghaith, Gusovsky, Fabian, Dagley, Jessica, Hong, David W., and O'Neil, Paul
- Subjects
FILARIASIS ,MONGOLIAN gerbil ,PARASITIC diseases ,ANTHELMINTICS ,ANIMAL diseases - Abstract
Lymphatic filariasis and onchocerciasis are two major neglected tropical diseases that are responsible for causing severe disability in 50 million people worldwide, whilst veterinary filariasis (heartworm) is a potentially lethal parasitic infection of companion animals. There is an urgent need for safe, short-course curative (macrofilaricidal) drugs to eliminate these debilitating parasite infections. We investigated combination treatments of the novel anti-Wolbachia azaquinazoline small molecule, AWZ1066S, with benzimidazole drugs (albendazole or oxfendazole) in up to four different rodent filariasis infection models: Brugia malayi--CB.17 SCID mice, B. malayi--Mongolian gerbils, B. pahangi--Mongolian gerbils, and Litomosoides sigmodontis-- Mongolian gerbils. Combination treatments synergised to elicit threshold (>90%) Wolbachia depletion from female worms in 5 days of treatment, using 2-fold lower dose-exposures of AWZ1066S than monotherapy. Short-course lowered dose AWZ1066S-albendazole combination treatments also delivered partial adulticidal activities and/or long-lasting inhibition of embryogenesis, resulting in complete transmission blockade in B. pahangi and L. sigmodontis gerbil models. We determined that short-course AWZ1066S-albendazole co-treatment significantly augmented the depletion of Wolbachia populations within both germline and hypodermal tissues of B. malayi female worms and in hypodermal tissues in male worms, indicating that anti-Wolbachia synergy is not limited to targeting female embryonic tissues. Our data provides pre-clinical proof-of-concept that sub-seven-day combinations of rapid-acting novel anti-Wolbachia agents with benzimidazole anthelmintics are a promising curative and transmission-blocking drug treatment strategy for filarial diseases ofmedical and veterinary importance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Repurposed Drugs That Activate Autophagy in Filarial Worms Act as Effective Macrofilaricides.
- Author
-
Voronin, Denis, Tricoche, Nancy, Peguero, Ricardo, Kaminska, Anna Maria, Ghedin, Elodie, Sakanari, Judy A., and Lustigman, Sara
- Subjects
FILARIAL worms ,FILARIASIS ,ONCHOCERCA volvulus ,AUTOPHAGY ,HUMAN reproduction - Abstract
Onchocerciasis and lymphatic filariasis are two neglected tropical diseases caused by filarial nematodes that utilize insect vectors for transmission to their human hosts. Current control strategies are based on annual or biannual mass drug administration (MDA) of the drugs Ivermectin or Ivermectin plus Albendazole, respectively. These drug regimens kill the first-stage larvae of filarial worms (i.e., microfilariae) and interrupt the transmission of infections. MDA programs for these microfilaricidal drugs must be given over the lifetime of the filarial adult worms, which can reach 15 years in the case of Onchocerca volvulus. This is problematic because of suboptimal responses to ivermectin in various endemic regions and inefficient reduction of transmission even after decades of MDA. There is an urgent need for the development of novel alternative treatments to support the 2030 elimination goals of onchocerciasis and lymphatic filariasis. One successful approach has been to target Wolbachia, obligatory endosymbiotic bacteria on which filarial worms are dependent for their survival and reproduction within the human host. A 4–6-week antibiotic therapy with doxycycline, for example, resulted in the loss of Wolbachia that subsequently led to extensive apoptosis of somatic cells, germline, embryos, and microfilariae, as well as inhibition of fourth-stage larval development. However, this long-course regimen has limited use in MDA programs. As an alternative approach to the use of bacteriostatic antibiotics, in this study, we focused on autophagy-inducing compounds, which we hypothesized could disturb various pathways involved in the interdependency between Wolbachia and filarial worms. We demonstrated that several such compounds, including Niclosamide, an FDA-approved drug, Niclosamide ethanolamine (NEN), and Rottlerin, a natural product derived from Kamala trees, significantly reduced the levels of Wolbachia in vitro. Moreover, when these compounds were used in vivo to treat Brugia pahangi-infected gerbils, Niclosamide and NEN significantly decreased adult worm survival, reduced the release of microfilariae, and decreased embryonic development depending on the regimen and dose used. All three drugs given orally significantly reduced Wolbachia loads and induced an increase in levels of lysosome-associated membrane protein in worms from treated animals, suggesting that Niclosamide, NEN, and Rottlerin were effective in causing drug-induced autophagy in these filarial worms. These repurposed drugs provide a new avenue for the clearance of adult worms in filarial infections. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Discovery of New Broad-Spectrum Anti-Infectives for Eukaryotic Pathogens Using Bioorganometallic Chemistry.
- Author
-
Lin, Yan, Jung, Hyeim, Bulman, Christina A., Ng, James, Vinck, Robin, O'Beirne, Cillian, Zhong, Shuai, Moser, Matthew S., Tricoche, Nancy, Peguero, Ricardo, Li, Robert W., Urban Jr., Joseph F., Le Pape, Patrice, Pagniez, Fabrice, Moretto, Marco, Weil, Tobias, Lustigman, Sara, Cariou, Kevin, Mitreva, Makedonka, and Sakanari, Judy A.
- Published
- 2023
- Full Text
- View/download PDF
7. Optimized strategy for real-time qPCR detection of Onchocerca volvulus DNA in pooled Simulium sp. blackfly vectors.
- Author
-
Doherty, Mary, Grant, Jessica R., Pilotte, Nils, Bennuru, Sasisekhar, Fischer, Kerstin, Fischer, Peter U., Lustigman, Sara, Nutman, Thomas B., Pfarr, Kenneth, Hoerauf, Achim, Unnasch, Thomas R., Hassan, Hassan K., Wanji, Samuel, Lammie, Patrick J., Ottesen, Eric, Mackenzie, Charles, and Williams, Steven A.
- Subjects
DISEASE eradication ,ONCHOCERCA volvulus ,SIMULIIDAE ,ONCHOCERCIASIS ,DISEASE relapse ,NEGLECTED diseases ,FISH parasites - Abstract
Background: Onchocerca volvulus is a filarial parasite that is a major cause of dermatitis and blindness in endemic regions primarily in sub-Saharan Africa. Widespread efforts to control the disease caused by O. volvulus infection (onchocerciasis) began in 1974 and in recent years, following successful elimination of transmission in much of the Americas, the focus of efforts in Africa has moved from control to the more challenging goal of elimination of transmission in all endemic countries. Mass drug administration (MDA) with ivermectin has reached more than 150 million people and elimination of transmission has been confirmed in four South American countries, with at least two African countries having now stopped MDA as they approach verification of elimination. It is essential that accurate data for active transmission are used to assist in making the critical decision to stop MDA, since missing low levels of transmission and infection can lead to continued spread or recrudescence of the disease. Methodology/Principal findings: Current World Health Organization guidelines for MDA stopping decisions and post-treatment surveillance include screening pools of the Simulium blackfly vector for the presence of O. volvulus larvae using a PCR-ELISA-based molecular technique. In this study, we address the potential of an updated, practical, standardized molecular diagnostic tool with increased sensitivity and species-specificity by comparing several candidate qPCR assays. When paired with heat-stable reagents, a qPCR assay with a mitochondrial DNA target (OvND5) was found to be more sensitive and species-specific than an O150 qPCR, which targets a non-protein coding repetitive DNA sequence. The OvND5 assay detected 19/20 pools of 100 blackfly heads spiked with a single L3, compared to 16/20 for the O150 qPCR assay. Conclusions/Significance: Given the improved sensitivity, species-specificity and resistance to PCR inhibitors, we identified OvND5 as the optimal target for field sample detection. All reagents for this assay can be shipped at room temperature with no loss of activity. The qPCR protocol we propose is also simpler, faster, and more cost-effective than the current end-point molecular assays. Author summary: Onchocerca volvulus is a nematode parasite that is the causative agent of river blindness in Africa, the Americas and Yemen and is transmitted by blackflies of the genus Simulium. Efforts to reduce and eliminate this neglected tropical disease focus on mass drug administration (MDA) with ivermectin and require reliable and accurate diagnostic assays to monitor the progress of once or twice-yearly treatments. One important measure of the impact of MDA is to screen pools of vector flies collected in endemic areas for the presence of L3-stage (infective) larvae. Since dissection of individual flies and microscopic examination to search for larvae in the flies is very time-consuming and results in many false negative and false positive results (due to morphologically similar larvae of closely related animal parasites), DNA-based PCR assays have proven extremely useful. An existing PCR-ELISA method based on amplification and detection of the O150 repeat found in the parasites has proven very useful over the last 25 years. An updated real-time qPCR-based method using a mitochondrial DNA target (OvND5) has now been developed that is more sensitive, more species specific, less-time consuming and less costly than the original O150 PCR-ELISA assay. This assay is ready for field evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Adjuvanted Fusion Protein Vaccine Induces Durable Immunity to Onchocerca volvulus in Mice and Non-Human Primates.
- Author
-
Ryan, Nathan M., Hess, Jessica A., Robertson, Erica J., Tricoche, Nancy, Turner, Cheri, Davis, Jenn, Petrovsky, Nikolai, Ferguson, Melissa, Rinaldi, William J., Wong, Valerie M., Shimada, Ayako, Zhan, Bin, Bottazzi, Maria Elena, Makepeace, Benjamin L., Gray, Sean A., Carter, Darrick, Lustigman, Sara, and Abraham, David
- Subjects
ONCHOCERCA volvulus ,CHIMERIC proteins ,PRIMATES ,MICE ,IMMUNITY - Abstract
Onchocerciasis remains a debilitating neglected tropical disease. Due to the many challenges of current control methods, an effective vaccine against the causative agent Onchocerca volvulus is urgently needed. Mice and cynomolgus macaque non-human primates (NHPs) were immunized with a vaccine consisting of a fusion of two O. volvulus protein antigens, Ov-103 and Ov-RAL-2 (Ov-FUS-1), and three different adjuvants: Advax-CpG, alum, and AlT4. All vaccine formulations induced high antigen-specific IgG titers in both mice and NHPs. Challenging mice with O. volvulus L3 contained within subcutaneous diffusion chambers demonstrated that Ov-FUS-1/Advax-CpG-immunized animals developed protective immunity, durable for at least 11 weeks. Passive transfer of sera, collected at several time points, from both mice and NHPs immunized with Ov-FUS-1/Advax-CpG transferred protection to naïve mice. These results demonstrate that Ov-FUS-1 with the adjuvant Advax-CpG induces durable protective immunity against O. volvulus in mice and NHPs that is mediated by vaccine-induced humoral factors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Development and validation of small animal models for onchocerciasis and loiasis microfilaricide discovery.
- Author
-
Ayiseh, Rene Bilingwe, Mbah, Glory Enjong, Monya, Elvis, Ndi, Emmanuel Menang, Sakanari, Judy, Lustigman, Sara, and Cho-Ngwa, Fidelis
- Subjects
ONCHOCERCIASIS ,ANIMAL welfare ,NEGLECTED diseases ,MONGOLIAN gerbil ,ANIMAL models in research - Abstract
Background: Onchocerciasis (river blindness) caused by the filarial worm Onchocerca volvulus is a neglected tropical disease that affects the skin and eyes of humans. Mass drug administration with ivermectin (IVM) to control the disease often suffers from severe adverse events in individuals co-injected with high loads of Loa loa microfilariae (mf). Thus loiasis animal models for counter-screening of compounds effective against onchocerciasis are needed, as are the corresponding onchocerciasis screening models. The repertoire of such models is highly limiting. Therefore, this study was aimed at developing and validating mf immunocompetent small animal models to increase tools for onchocerciasis drug discovery. Methodology/Principal findings: O. ochengi mf from cattle skin and L. loa mf from human blood were used to infect BALB/c mice and Mongolian gerbils, and IVM was used for model validation. O. ochengi mf were given subcutaneously to both rodents while L. loa mf were administered intravenously to mice and intraperitoneally to gerbils. IVM was given orally. In an 8-day model of O. ochengi mf in BALB/c mice, treatment with IVM depleted all mf in the mice, unlike the controls. Also, in a 2.5-day model of L. loa mf in BALB/c, IVM significantly reduced mf in treated mice compared to the untreated. Furthermore, the gerbils were very susceptible to O. ochengi mf and IVM eradicated all mf in the treated animals. In the peritoneal L. loa mf gerbil model, IVM reduced mf motility in treated animals compared to the controls. In a 30-day gerbil co-injection model, IVM treatment cleared all O. ochengi mf and reduced motility of L. loa mf. Both mf survived for up to 50 days in a gerbil co-injection model. Conclusions/Significance: We have developed two immunocompetent small animal models for onchocerciasis and loiasis that can be used for microfilaricide discovery and to counter-screen onchocerciasis macrofilarides Author summary: Onchocerciasis (river blindness) caused by the filarial worm Onchocerca volvulus is a severe skin disease and affects the eyes leading to vision loss. Drugs that are effective against O. volvulus should be ineffective against another filarial worm Loa loa, as severe adverse events has been reported in treated co-infected individuals. Thus, animal models are needed to screen for compounds effective against onchocerciasis but not against the Loa loa microfilariae (mf). O. ochengi mf from cattle skin and L. loa mf from human blood were used to infect BALB/c mice and Mongolian gerbils, and ivermectin (IVM) was used for model validation. O. ochengi mf survived both animals and treatment with IVM significantly reduced the number of mf. In a BALB/c L. loa mf model, IVM significantly reduced mf in treated mice compared to the untreated. L. loa mf survived in peritoneum of gerbils. A gerbil co-injection model (with both O. ochengi and L. loa mf) was developed and both mf survived for up to 50 days in this model. In conclusion, we have developed two immunocompetent small animal models for onchocerciasis and loiasis that can be used for microfilaricide discovery. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. The Th1/Tfh-like biased responses elicited by the rASP-1 innate adjuvant are dependent on TRIF and Type I IFN receptor pathways.
- Author
-
George, Parakkal Jovvian, Marches, Radu, Nehar-Belaid, Djamel, Banchereau, Jacques, and Lustigman, Sara
- Subjects
T helper cells ,TH1 cells ,TYPE I interferons ,INTERFERON receptors ,T cells - Abstract
Ov-ASP-1 (rASP-1), a parasite-derived protein secreted by the helminth Onchocerca volvulus, is an adjuvant which enhances the potency of the influenza trivalent vaccine (IIV3), even when used with 40-fold less IIV3. This study is aimed to provide a deeper insight into the molecular networks that underline the adjuvanticity of rASP-1. Here we show that rASP-1 stimulates mouse CD11c+ bone marrow-derived dendritic (BMDCs) to secrete elevated levels of IL-12p40, TNF-a, IP-10 and IFN-b in a TRIF-dependent but MyD88-independent manner. rASP-1-activated BMDCs promoted the differentiation of naïve CD4+ T cells into Th1 cells (IFN-g+) that was TRIF- and type I interferon receptor (IFNAR)-dependent, and into Tfh-like cells (IL21+) and Tfh1 (IFN-g+ IL21+) that were TRIF-, MyD88- and IFNAR-dependent. rASP-1-activated BMDCs promoted the differentiation of naïve CD4+ T cells into Th17 (IL-17+) cells only when the MyD88 pathway was inhibited. Importantly, rASP-1-activated human blood cDCs expressed upregulated genes that are associated with DC maturation, type I IFN and type II IFN signaling, as well as TLR4-TRIF dependent signaling. These activated cDCs promoted the differentiation of naïve human CD4+ T cells into Th1, Tfh-like and Th17 cells. Our data thus confirms that the rASP-1 is a potent innate adjuvant that polarizes the adaptive T cell responses to Th1/Tfh1 in both mouse and human DCs. Notably, the rASP-1-adjuvanted IIV3 vaccine elicited protection of mice from a lethal H1N1 infection that is also dependent on the TLR4-TRIF axis and IFNAR signaling pathway, as well as on its ability to induce anti-IIV3 antibody production. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Co-Administration of Adjuvanted Recombinant Ov -103 and Ov -RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine Onchocerca ochengi Infection Model of Human Onchocerciasis.
- Author
-
Luu, Lisa, Bah, Germanus S., Okah-Nnane, Ndode Herman, Hartley, Catherine S., Glover, Alexandra F., Walsh, Tessa R., Lian, Lu-Yun, Zhan, Bin, Bottazzi, Maria Elena, Abraham, David, Petrovsky, Nikolai, Bayang, Nicolas, Tangwa, Bernard, Ayiseh, Rene Billingwe, Mbah, Glory Enjong, Ekale, David D., Tanya, Vincent N., Lustigman, Sara, Makepeace, Benjamin L., and Graham-Brown, John
- Subjects
IVERMECTIN ,ONCHOCERCIASIS ,BACTERIAL vaccines ,NEGLECTED diseases ,ONCHOCERCA volvulus ,CATTLE parasites ,VACCINES - Abstract
Onchocerciasis (river blindness), caused by the filarial nematode Onchocerca volvulus, is a neglected tropical disease mainly of sub-Saharan Africa. Worldwide, an estimated 20.9 million individuals live with infection and a further 205 million are at risk of disease. Current control methods rely on mass drug administration of ivermectin to kill microfilariae and inhibit female worm fecundity. The identification and development of efficacious vaccines as complementary preventive tools to support ongoing elimination efforts are therefore an important objective of onchocerciasis research. We evaluated the protective effects of co-administering leading O. volvulus-derived recombinant vaccine candidates (Ov-103 and Ov-RAL-2) with subsequent natural exposure to the closely related cattle parasite Onchocerca ochengi. Over a 24-month exposure period, vaccinated calves (n = 11) were shown to acquire infection and microfilaridermia at a significantly lower rate compared to unvaccinated control animals (n = 10). Furthermore, adult female worm burdens were negatively correlated with anti-Ov-103 and Ov-RAL-2 IgG1 and IgG2 responses. Peptide arrays identified several Ov-103 and Ov-RAL-2-specific epitopes homologous to those identified as human B-cell and helper T-cell epitope candidates and by naturally-infected human subjects in previous studies. Overall, this study demonstrates co-administration of Ov-103 and Ov-RAL-2 with Montanide™ ISA 206 VG is highly immunogenic in cattle, conferring partial protection against natural challenge with O. ochengi. The strong, antigen-specific IgG1 and IgG2 responses associated with vaccine-induced protection are highly suggestive of a mixed Th1/Th2 associated antibody responses. Collectively, this evidence suggests vaccine formulations for human onchocerciasis should aim to elicit similarly balanced Th1/Th2 immune responses. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Aspartyl Protease Inhibitors as Anti-Filarial Drugs.
- Author
-
Beld, Liana, Jung, Hyeim, Bulman, Christina A., Rosa, Bruce A., Fischer, Peter U., Janetka, James W., Lustigman, Sara, Sakanari, Judy A., and Mitreva, Makedonka
- Subjects
NEMATODE infections ,PROTEASE inhibitors ,FILARIASIS ,ONCHOCERCA volvulus ,PROTEIN kinases ,PROTEOLYTIC enzymes ,IVERMECTIN - Abstract
The current treatments for lymphatic filariasis and onchocerciasis do not effectively kill the adult parasitic nematodes, allowing these chronic and debilitating diseases to persist in millions of people. Thus, the discovery of new drugs with macrofilaricidal potential to treat these filarial diseases is critical. To facilitate this need, we first investigated the effects of three aspartyl protease inhibitors (APIs) that are FDA-approved as HIV antiretroviral drugs on the adult filarial nematode, Brugia malayi and the endosymbiotic bacteria, Wolbachia. From the three hits, nelfinavir had the best potency with an IC
50 value of 7.78 µM, followed by ritonavir and lopinavir with IC50 values of 14.3 µM and 16.9 µM, respectively. The three APIs have a direct effect on killing adult B. malayi after 6 days of exposure in vitro and did not affect the Wolbachia titers. Sequence conservation and stage-specific gene expression analysis identified Bm8660 as the most likely primary aspartic protease target for these drug(s). Immunolocalization using antibodies raised against the Bm8660 ortholog of Onchocerca volvulus showed it is strongly expressed in female B. malayi, especially in metabolically active tissues such as lateral and dorsal/ventral chords, hypodermis, and uterus tissue. Global transcriptional response analysis using adult female B. pahangi treated with APIs identified four additional aspartic proteases differentially regulated by the three effective drugs, as well as significant enrichment of various pathways including ubiquitin mediated proteolysis, protein kinases, and MAPK/AMPK/FoxO signaling. In vitro testing against the adult gastro-intestinal nematode Trichuris muris suggested broad-spectrum potential for these APIs. This study suggests that APIs may serve as new leads to be further explored for drug discovery to treat parasitic nematode infections. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi.
- Author
-
Zhan, Bin, Bottazzi, Maria Elena, Hotez, Peter J., and Lustigman, Sara
- Subjects
ONCHOCERCIASIS ,FILARIASIS ,ONCHOCERCA volvulus ,VACCINE development ,INFECTION ,CATTLE diseases ,NEMATODE infections - Abstract
Human onchocerciasis is a devastating neglected tropical disease caused by infection of the filarial nematode Onchocerca volvulus. The infection can cause irreversible visual impairment or blindness and stigmatizing dermatitis. More than 32 million people were estimated to be infected with O. volvulus in Africa, and 385,000 suffered from blindness. Even though the implementation of mass drug administration (MDA) with ivermectin has reduced the global prevalence of onchocerciasis, O. volvulus infection remains challenging to control because MDA with ivermectin cannot be implemented in endemic areas co-endemic with loiasis due to the risk of severe adverse events. There is also emerging drug resistance to ivermectin that further complicates the elimination of onchocerciasis. Thus, the development of a vaccine that would induce protective immunity and reduce infection burden is essential. Efforts to develop prophylactic and/or therapeutic vaccines for onchocerciasis have been explored since the late 1980s by many researchers and entities, and here we summarize the recent advances made in the development of vaccines against the infection of O. volvulus and onchocerciasis. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Development of a recombinant vaccine against human onchocerciasis.
- Author
-
Abraham, David, Graham-Brown, John, Carter, Darrick, Gray, Sean A., Hess, Jessica A., Makepeace, Benjamin L., and Lustigman, Sara
- Subjects
ONCHOCERCIASIS ,VACCINE development ,ONCHOCERCA volvulus ,VACCINE trials ,CHIMERIC proteins - Abstract
Human onchocerciasis caused by the filarial nematode parasite Onchocerca volvulus remains a major cause of debilitating disease infecting millions primarily in Sub-Saharan Africa. The development of a prophylactic vaccine, along with mass drug administration, would facilitate meeting the goal of onchocerciasis elimination by 2030. Models used to study immunity to Onchocerca include natural infection of cattle with Onchocerca ochengi and O. volvulus infective third-stage larvae implanted within diffusion chambers in mice. A vaccine, comprised of two adjuvanted recombinant antigens, induced protective immunity in genetically diverse mice suggesting that it will function similarly in diverse human populations. These antigens were recognized by immune humans and also induced protective immunity against Brugia malayi. We describe the development of a fusion protein composed of the two vaccine antigens with the plan to test the vaccine in cows and non-human primates as a prelude to the initiation of phase 1 clinical trials. The adjuvanted O. volvulus vaccine composed of two antigens Ov-103 and Ov-RAL-2 was shown to be consistently effective at inducing protective immunity using multiple immune mechanisms. The vaccine is ready for further evaluation in other animal models before moving to clinical trials in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. Pyrvinium Pamoate and Structural Analogs Are Early Macrofilaricide Leads.
- Author
-
Gunderson, Emma L., Bryant, Clifford, Bulman, Christina A., Fischer, Chelsea, Luo, Mona, Vogel, Ian, Lim, Kee-Chong, Jawahar, Shabnam, Tricoche, Nancy, Voronin, Denis, Corbo, Christopher, Ayiseh, Rene B., Manfo, Faustin P. T., Mbah, Glory E., Cho-Ngwa, Fidelis, Beerntsen, Brenda, Renslo, Adam R., Lustigman, Sara, and Sakanari, Judy A.
- Subjects
FILARIAL worms ,FILARIASIS ,ONCHOCERCIASIS ,DRUG administration ,TROPICAL medicine ,MEDICAL screening - Abstract
Onchocerciasis and lymphatic filariasis are neglected tropical diseases caused by infection with filarial worms. Annual or biannual mass drug administration with microfilaricidal drugs that kill the microfilarial stages of the parasites has helped reduce infection rates and thus prevent transmission of both infections. However, success depends on high population coverage that is maintained for the duration of the adult worm's lifespan. Given that these filarial worms can live up to 14 years in their human hosts, a macrofilaricidal drug would vastly accelerate elimination efforts. Here, we have evaluated the repurposed drug pyrvinium pamoate as well as newly synthesized analogs of pyrvinium for their efficacy against filarial worms in vitro and in vivo. We found that pyrvinium pamoate, tetrahydropyrvinium and one of the analogs were highly potent in inhibiting worms in in vitro whole-worm screening assays, and that all three compounds reduced female worm fecundity and inhibited embryogenesis in the Brugia pahangi-gerbil in vivo model of infection. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.